Inflammatory Acne Treatment: Review of Current and New Topical Therapeutic Options

28. Morelli R, Lanzarini M, Vincenzi C, Reggiani M. Contact dermatitis due to benzoyl peroxide. Contact Dermatitis. 1989;20(3):238-239.
29. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin. Pharmacother. 2009;10(15):2555-2562.
30. Dosik JS, Vamvakias G. Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers. Am J Clin Dermatol. 2008;9(5):313-317.
31. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25(10):664-667.
32. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265.
33. Leyden JJ, Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clinical Aesthet Dermatol. 2011;4(2):40-47.
34. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology. 1998;196(1):130-134.
35. Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis. 2008;82(6):417-421.
36. Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis. 2010;85(1):15-24.
37. Whitney KM, Ditre CM. Anti-inflammatory properties of clindamycin: a review of its use in the treatment of acne vulgaris. Dermatology. 2011;4:27-41.
38. Guay DR. Topical clindamycin in the management of acne vulgaris. Expert Opin Pharmacother. 2007;8(15):2625-2664.
39. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27(1):33-42.
40. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117-1133.
41. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41-47.
42. Draelos ZD, Ertel KD, Berge CA. Facilitating facial retinization through barrier improvement. Cutis. 2006;78(4):275-281.
43. Zeichner JA, Patel RV, Haddican M, Wong V. Efficacy and safety of a ceramide containing moisturizer followed by fixed-dose clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel in the morning in combination with a ceramide containing moisturizer followed by tretinoin 0.05% gel in the evening for the treatment of facial acne vulgaris. J Drugs Dermatol. 2012;11(6):748-752.
44. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628-1635.
45. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420-434.
46. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.
47. Fleischer AB, Shalita A, Eichenfield LF, et al. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. J Drugs Dermatol. 2010;9(1):33-40.
48. Tanghetti E, Dhawan S, Green L, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10(7):783-792.
49. Onexton [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014.
50. Bucks DAW, Pillai RS, McCall-Perez F. Advances in formulation technologies: creating highly effective and well-tolerated topical dermatologicals. Skin & Aging. 2010;(suppl):s4-s6.
51. Lee MS, Kossard S, Wilkinson B, and Doyle JA .Quantification of hair follicle parameters using computer image analysis: a comparison of androgenetic alopecia with normal scalp biopsies. Australas J Dermatol. 1995;36(3):143-147.
52. Pariser DM, Rich P, Cook-Bolden FE, Korotzer A. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083-1089.
53. Stein Gold L. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. J Drugs Dermatol. 2015;14(9):969-974.
54. Zeichner JA. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in adult female patients with facial acne vulgaris. J Clin Aesthet Dermatol. 2015;8(4):21-25.
55. Cook-Bolden FE. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. J Clin Aesthet Dermatol. 2015;8(5):28-32.
56. Bhatia N, Pillai R. Randomized, observer-blind, split-face compatibility study with clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel and facial foundation makeup. J Clin Aesthet Dermatol. 2015;8(9):25-32.
57. Epiduo Forte [prescribing information]. Fort Worth, TX: Galderma; 2015.
58. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57(5):791-799.
59. Gollnick, HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-1189.
60. Sevin K, Osman-Ponchet H, Gaborit A, et al. Fixed-combination adapalene 0.3%/benzoyl peroxide 2.5% gel provides optimal percutaneous absorption compared to monad formulations of these compounds: a bioequivalence study. Poster presented at the Fall Clinical Dermatology Conference. Las Vegas, NV. October 2014.
61. Weiss J, Stein-Gold L, Tanghetti E. et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel versus vehicle in moderate and severe acne vulgaris. Poster presented at the Fall Clinical Dermatology Conference. Las Vegas, NV. October 2014.
62. Safety and efficacy study of dapsone gel in patients with acne vulgaris. https://clinicaltrials.gov/ct2/show/record/NCT01974323. Accessed November 28, 2015.
63. Hunt DWC, Hofland HEJ. DRM01, a novel acetyl conenzyme A carboxylase (ACC) inhibitor, reduces sebum production. Poster presented at the Society for Investigative Dermatology Annual Meeting; Albuquerque, NM. May 2014.
64. Bissonnette R, Poulin Y, Drew J, et al. Early onset of action in a randomized, vehicle-controlled phase 2a study of DRM01, a novel topical sebum inhibitor, in subjects with acne vulgaris. Poster presented at the Fall Clinical Dermatology Conference. Las Vegas, NV. October 2014.
65. Stein-Gold L, Shemer A, Sprecher E, et al. A phase 2 randomized trial of a new minocycline foam for the treatment of moderate to severe acne vulgaris. Poster presented at the South Beach Dermatology Symposium. Miami, FL. Feburary 2014.
66. Rico J, Quiring J, Hollenbach S, et al. Phase 2 study of efficacy and safety of SB204 in the treatment of acne vulgaris. Poster presented at the Annual Meeting of the Society for Investigative Dermatology. Albuquerque, NM. May 2014.
67. Nestor MS, Gold MH, Kauvar AN. The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol. 2006;5(2):140-154.
68. Paithankar DY, Sakamoto FH, Farinelli WA, et al. Acne treatment based on selective photothermolysis of sebaceous follicles with topically delivered light-absorbing gold microparticles. J Invest Dermatol. 2015;135(7):1727-1734.

AUTHOR CORRESPONDENCE